Atuka is pleased to present the third entry in our Discovery Series on Emerging Targets in Parkinson’s Disease, examining leucine-rich repeat kinase 2 (LRRK2) as a route toward disease-modifying therapy in Parkinson’s disease (PD).
Authored by Atuka’s co-founder Dr. Michael Hill, this review surveys the biology, clinical pipeline, and translational challenges of LRRK2-targeted therapeutics, and argues that the field has moved from a question of target validation to one of translational optimization: how best to modulate LRRK2 safely and durably across a biologically diverse patient population.
Why LRRK2?
- A Mechanistic Hub, Not a Narrow Genetic Target
LRRK2 sits at the intersection of several PD-relevant processes, including vesicular trafficking, lysosomal and autophagic function, mitochondrial homeostasis, and immune signalling. All pathogenic mutations converge on a gain-of-function increase in kinase activity and downstream Rab GTPase phosphorylation. Because elevated LRRK2 activity is also detected in subsets of idiopathic PD, the target’s relevance extends well beyond mutation carriers. - A Heterogeneous Disease Behind a Single Label
“LRRK2-PD” represents a biological spectrum rather than a single disease entity, with substantial variability in penetrance, age of onset, progression, and α-synuclein and tau pathology. The key question for model selection becomes which aspect of LRRK2-linked biology a model captures, which calls for a mechanism-led rather than label-led approach. - A Pipeline That Maps the Open Questions
Small-molecule kinase inhibitors, brain-selective designs, targeted protein degraders, and RNA-based approaches are all advancing in parallel. That diversity reflects unresolved questions about how best to modulate LRRK2 across tissues, disease stages, and biological contexts, and offers a way to read the translational design space.
What You’ll Learn
- LRRK2 Biology and Mechanism
How pathogenic mutations drive Rab hyperphosphorylation and propagate across autophagy-lysosomal, synaptic, mitochondrial, and neuroinflammatory pathways, and why these mechanisms are not confined to mutation carriers. - The Clinical and Preclinical Landscape
A program-by-program overview spanning CNS-penetrant kinase inhibitors (Denali/Biogen’s BIIB122, Neuron23’s NEU-411, Brenig’s BT-267), a PROTAC degrader (Arvinas’ ARV-102), and antisense approaches (Biogen’s BIIB094, SciNeuro’s SNP-614), set against the LUMA Phase 2b readout and the MJFF LITE collaborative program. - Safety as a Translational Design Constraint
Why LRRK2 safety is best understood as a function of how the target is modulated, including peripheral on-target effects in lung and kidney observed preclinically, and how brain-selective, degrader, and RNA-based modalities reshape the benefit–risk question. - The Strategic Role of Non-Human Primates
Where NHP studies add the most value, deployed selectively to resolve CNS-versus-peripheral exposure, durability of target engagement, modality-dependent effects, and biomarker relationships relevant to human studies, in line with 3Rs principles.
Download the Full Report
LRRK2-targeted therapies for the treatment of Parkinson’s disease
A detailed review of LRRK2 biology, the current therapeutic pipeline, and the translational considerations that will determine whether mechanistic validation becomes clinical benefit.
Related Reading
As world leaders in Parkinson’s research, with a proven track record evaluating over 300 potential therapeutics, Atuka’s scientists bring decades of experience in designing preclinical studies that deliver actionable results.
Explore our thinking:
- Video lecture: Aligning in vivo models of Parkinson’s disease with biological classifications
- Discovery Series #2: BDNF/TrkB Pathway Modulation
- Discovery Series #1: D1 Dopamine Receptor Positive Allosteric Modulators (D1 PAMs)
- Optimizing Preclinical Studies for Parkinson’s Disease Therapeutics
- The Future of Gene Therapy
Contact Us
To discuss how Atuka can help design and de-risk preclinical programs targeting BDNF/TrkB and other neurotrophic pathways, please reach out or schedule a conversation via our contact page.